Parkinson’s vaccine candidate Affitope PD01, along with maker Affiris’ portfolio of other alpha-synuclein-targeting therapies, was acquired by AC Immune in a recent deal valued at nearly $60 million. “We believe very strongly that active vaccination will play an important role in the long-term management and possible prevention of…

Multiple administrations of Affitope PD01A, an investigational vaccine for Parkinson’s disease, elicit a safe and sustained immune response against alpha-synuclein — a protein involved in the development of Parkinson’s — in patients at the early stages of the disease, according to results from a Phase 1…

The U.S. Food and Drug Administration (FDA) has responded to Affiris‘  pre-investigational new drug (IND) submission regarding a planned Phase 2 clinical trial of the potential Parkinson’s vaccine Affitope (PD01A). After reviewing previous preclinical and clinical data, the FDA answered questions posed by the company…

Affiris is preparing for a Phase 2 clinical trial to test Affitope (PD01A), an experimental medicine that, if successful, could lead to a vaccine against  Parkinson’s disease. Affitope triggers the production of antibodies — molecules that recognize specific targets — against alpha-synuclein, a protein found in the…

Affiris’ experimental Parkinson’s vaccine, Affitope PD01A, is safe and effectively triggers an immune response against the alpha-synuclein (aSyn) protein, data from a series of four consecutive clinical trials show. Results from the so-called AFF008 study program were recently presented at the Advances in Alzheimer’s and Parkinson’s Therapies Focus Meeting (AAT-AD/PD) in…

AFFiRiS’s new Parkinson’s vaccine, AFFITOPE PD03A, triggered a solid immune response against the alpha-Synuclein (aSyn) protein associated with the disease, according to a Phase 1 clinical trial. Patients also tolerated the therapy well, researchers said. Werner Poewe, a professor at Austria’s Medical University Insbruck, presented the results at the 21stInternational Congress…